Integral Diagnostics Ltd. (IDX) AI Stock Analysis

• Market Cap: AU$947.23M
• Dividend Yield: 2.65%
• Average Volume (3M): 911.20K
• Price to Earnings (P/E): 167.1
• Beta (1Y): 0.36
• Revenue Growth: 33.54%
• EPS Growth: N/A
• Country: AU
• Employees: 1,977
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.07
• Shares Outstanding: 372,926,670
• 10 Day Avg. Volume: 1,057,226
• 30 Day Avg. Volume: 911,197
• PEG Ratio: -1.57
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.24
• P/FCF Ratio: 55.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$3.22
• Price Target Upside: 26.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: AU$3.00 ▲(18.11% Upside)

Integral Diagnostics Ltd. has strong revenue growth and operational efficiency, but faces significant challenges in profitability and cash flow management. The technical indicators suggest bearish momentum, and the stock appears overvalued with a high P/E ratio. These factors contribute to a cautious outlook, reflected in the overall score.

Positive Factors

Revenue Growth

Strong revenue growth reflects robust market demand and effective service delivery, positioning the company well for future expansion.

Operational Efficiency

High gross profit margins indicate effective cost management and pricing power, supporting long-term profitability potential.

Improved Leverage

Improved leverage suggests better financial management and reduced risk, enhancing financial stability and flexibility.

Negative Factors

Low Net Profit Margin

Low net profit margins indicate difficulty in converting sales into actual profit, which could hinder sustainable financial growth.

Declining Free Cash Flow

A significant decline in free cash flow raises concerns about liquidity and the ability to fund operations and growth initiatives.

Low Return on Equity

Low return on equity suggests inefficient use of shareholder funds, potentially limiting investor appeal and future capital raising.

Integral Diagnostics Ltd. Business Overview & Revenue Model

Company Description

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.

How the Company Makes Money

Integral Diagnostics generates revenue primarily through the provision of diagnostic imaging services to patients and healthcare professionals. The company's revenue model is based on billing for individual imaging procedures, which are often covered by public and private health insurance schemes. Key revenue streams include payments from health insurers, direct payments from patients, and government funding for specific services. Additionally, IDX benefits from strategic partnerships with hospitals and healthcare providers, which help secure a steady flow of referrals for imaging services. The company also invests in expanding its service offerings and enhancing operational efficiencies to drive profitability.

Integral Diagnostics Ltd. Financial Statement Overview

Summary

Integral Diagnostics Ltd. shows strong revenue growth and operational efficiency, as evidenced by high gross profit margins. However, the company faces challenges in converting this growth into net income, reflected in low net profit margins and return on equity. The balance sheet shows improved leverage, but cash flow concerns persist due to declining free cash flow. Overall, while the company is on a growth trajectory, it needs to focus on enhancing profitability and cash flow management to ensure sustainable financial health.

Income Statement

Integral Diagnostics Ltd. has demonstrated strong revenue growth with a 27.66% increase in the latest year, indicating a robust expansion trajectory. The gross profit margin remains high at 95.52%, showcasing operational efficiency. However, the net profit margin is low at 0.75%, suggesting challenges in translating revenue growth into net income. The EBIT and EBITDA margins are moderate, reflecting stable operational performance but room for improvement in cost management.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.84, indicating a better balance between debt and equity compared to previous years. However, the return on equity is low at 0.67%, pointing to limited profitability for shareholders. The equity ratio is stable, suggesting a solid asset base, but the company needs to enhance its profitability metrics to strengthen its financial position further.

Cash Flow

Operating cash flow remains positive, but the free cash flow has declined significantly by 58.96%, raising concerns about cash generation capabilities. The operating cash flow to net income ratio is moderate, indicating some efficiency in converting income into cash. However, the free cash flow to net income ratio is low, suggesting potential liquidity challenges if the trend continues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	627.22M	627.22M	469.70M	440.10M	358.74M	348.81M
Gross Profit	163.28M	599.09M	446.78M	97.76M	83.84M	92.19M
EBITDA	96.64M	87.70M	12.10M	92.74M	69.90M	88.94M
Net Income	4.67M	4.67M	-60.70M	25.04M	14.60M	31.27M
Balance Sheet
Total Assets	1.43B	1.43B	744.28M	839.01M	783.01M	654.90M
Cash, Cash Equivalents and Short-Term Investments	52.10M	52.10M	42.44M	33.85M	123.19M	62.20M
Total Debt	585.01M	585.01M	355.59M	365.08M	340.99M	308.36M
Total Liabilities	732.53M	732.53M	442.57M	465.96M	435.77M	400.16M
Stockholders Equity	693.00M	693.00M	301.71M	373.05M	347.24M	254.74M
Cash Flow
Free Cash Flow	14.01M	14.01M	42.28M	27.42M	9.33M	49.30M
Operating Cash Flow	73.77M	73.77M	66.16M	71.42M	37.10M	69.57M
Investing Cash Flow	-64.99M	-64.99M	-27.90M	-128.96M	-55.69M	-56.66M
Financing Cash Flow	710.00K	710.00K	-29.45M	-31.85M	81.13M	-7.83M

Integral Diagnostics Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.54
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Positive. The current price of 2.54 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.52, and above the 200-day MA of 2.54, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.34 is Neutral, neither overbought nor oversold. The STOCH value of 73.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDX.

Integral Diagnostics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	71 Outperform	AU$520.92M	15.80	18.59%	4.60%	6.73%	37.16%
MVF	67 Neutral	AU$292.23M	11.68	10.25%	6.22%	6.65%	―
SHL	64 Neutral	AU$11.07B	20.94	6.32%	4.69%	9.44%	-0.37%
IDX	55 Neutral	AU$947.23M	167.11	0.94%	2.65%	33.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	50 Neutral	AU$707.98M	-1.35	-67.21%	―	-23.02%	33.11%
GSS	41 Neutral	AU$53.38M	-2.60	-36.16%	―	62.81%	16.37%

Integral Diagnostics Ltd. Corporate Events

Integral Diagnostics CEO Increases Shareholding After Vesting of Incentive Rights

Integral Diagnostics Ltd has disclosed a change in the interests of director Ian Kadish following the vesting of short-term incentive (STI) performance rights. On 22 December 2025, 34,233 STI performance rights vested into fully paid ordinary shares, increasing Kadish’s direct shareholding from 639,548 to 673,781 shares, while his STI performance rights balance decreased accordingly and his long-term incentive (LTI) performance rights holdings rose slightly due to adjustments. The transaction, undertaken for nil cash consideration, reflects the execution of the company’s incentive arrangements and further aligns the chief executive’s equity exposure with shareholder interests.

The most recent analyst rating on (AU:IDX) stock is a Sell with a A$2.10 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues 99,221 New Shares on Option Conversion

Integral Diagnostics Ltd has issued 99,221 new fully paid ordinary shares on 22 December 2025 following the exercise or conversion of previously unquoted options or other convertible securities. The move modestly increases the company’s share base and reflects the take-up of equity incentives by holders of these instruments, slightly diluting existing shareholders while converting unquoted rights into listed equity.

The most recent analyst rating on (AU:IDX) stock is a Sell with a A$2.10 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Updates Director’s Securities Holdings

Integral Diagnostics Ltd. has announced a change in the director’s interest notice for Ian Kadish, reflecting updates in the company’s securities holdings. The notice details the acquisition of 120,928 Short-Term Incentive (STI) Rights and 114,668 Long-Term Incentive (LTI) Rights, with no disposals reported. This change signifies an adjustment in the director’s performance rights, which may impact the company’s governance and incentive structures.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues New Performance Rights Under Employee Incentive Scheme

Integral Diagnostics Ltd. has announced the issuance of 71,911 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s commitment to incentivizing its workforce and aligning employee interests with corporate performance.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues Performance Rights Under Employee Incentive Scheme

Integral Diagnostics Ltd. has announced the issuance of 114,688 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize and retain key personnel, potentially impacting its operational efficiency and stakeholder engagement.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues New Performance Rights

Integral Diagnostics Ltd. announced the issuance of 3,148 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s efforts to incentivize and retain talent, potentially impacting its operational effectiveness and stakeholder engagement.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues Performance Rights to Boost Talent Retention

Integral Diagnostics Ltd. has announced the issuance of 296,527 performance rights under an employee incentive scheme, which are unquoted and subject to transfer restrictions. This move is part of the company’s strategy to incentivize and retain talent, potentially enhancing its operational capabilities and market position in the diagnostic imaging sector.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Appoints New CEO to Drive Growth and Innovation

Integral Diagnostics (IDX) has appointed Jason Martinez as its new Managing Director and Chief Executive Officer, succeeding Dr. Ian Kadish, who will retire at the end of FY26. Martinez, who brings over 20 years of experience in the diagnostic imaging and health sectors, is expected to drive growth through organic means and mergers and acquisitions, leveraging AI capabilities and focusing on margin improvement. His appointment is seen as a strategic move to continue delivering excellent patient care and improving returns for investors, positioning IDX as a leading force in the diagnostic imaging industry.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Secures Strong Shareholder Support at AGM

Integral Diagnostics Limited announced that all resolutions at its Annual General Meeting were passed, reflecting strong shareholder support. The successful resolutions, including the election of directors and approval of financial assistance, indicate stability and continued confidence in the company’s strategic direction.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Reports Strong FY25 Performance and Strategic Growth

Integral Diagnostics Ltd. has reported strong financial performance for FY25, driven by its successful merger with Capitol Health, which has exceeded synergy expectations. The company is well-positioned for further growth due to industry tailwinds and strategic initiatives in sustainability, including a focus on environmental, social, and governance responsibilities. IDX’s increased scale and improved margins position it to capitalize on future M&A opportunities and industry consolidation.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics to Release Shares from Escrow

Integral Diagnostics Limited announced the release of 876,068 fully paid ordinary shares from voluntary escrow on November 1, 2025. This release will not affect the company’s issued capital, indicating a stable financial position and potentially reassuring stakeholders about the company’s operational consistency.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues New Performance Rights

Integral Diagnostics Ltd. announced the issuance of 677 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX, indicating a strategic move to incentivize employees and align their interests with company performance.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues New Performance Rights

Integral Diagnostics Ltd. announced the issuance of 214,921 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until these restrictions are lifted, potentially impacting employee retention and motivation.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Issues New Performance Rights Under Incentive Scheme

Integral Diagnostics Ltd. announced the issuance of 829,926 performance rights under an employee incentive scheme. These unquoted securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, potentially impacting employee retention and motivation strategies.

The most recent analyst rating on (AU:IDX) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Ltd. Announces Quotation of New Securities

Integral Diagnostics Ltd. has announced the application for quotation of 299,862 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of a dividend or distribution plan, potentially impacting the company’s financial structure and market presence by increasing its available capital and shareholder base.

The most recent analyst rating on (AU:IDX) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.

Integral Diagnostics Announces 2025 Annual General Meeting Details

Integral Diagnostics Ltd. has announced its 2025 Annual General Meeting scheduled for 31 October 2025, allowing shareholders to participate either in person or online. This meeting is a significant event for the company as it provides an opportunity for stakeholders to engage with the company’s leadership and discuss future strategies, potentially impacting its operations and market positioning.

The most recent analyst rating on (AU:IDX) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.